



Venture Capital - Life Sciences

Life Sciences supports promising companies in the life sciences sector. Gimv's characteristic long-term approach is particularly valuable in this capital-intensive sector, which is marked by cyclical fluctuations. The period between initial investment and exit is often long and unpredictable. To maximise return on investment and create short and long-term value for the companies we invest in, Life Sciences is committed to active involvement at board of director level.

Investment criteria

Life Sciences invests in companies that meet the following criteria:

- led by committed, ambitious management teams;
- developing innovative first-in-class or best-in-class products or services;
- having a sustainable competitive advantage.

Investment focus

The Life Sciences division supports innovative biotech companies developing first-in-class or best-in-class products for growth markets, active in various areas:

- therapeutics;
- diagnostics;
- medical devices;
- technologies to be applied in agriculture or in
- white (industrial) biotech.

Portfolio

7TM Pharma, Ablynx, Acertys, Actogenix, Ambit, Antisoma, Astex Therapeutics, Ceres, ChemoCentryx, Endosense, Innate Pharma, JenaValve, Nereus Pharmaceuticals, PamGene, Plexxikon, Pronota, Prosensa, Santhera Pharmaceuticals

Buyouts & Growth

- Belgium
- Netherlands
- France
- Germany (Halder)

Venture Capital

- Technology
- Cleantech
- Life Sciences

Funds & Joint Ventures

- **Gimv-XL:**
investments in larger growth companies in Flanders
- **Gimv-Agri+:**
investments in the agricultural sector in the Benelux and neighbouring countries
- **Central Europe & Russia:**
private equity investments in, amongst others, Russia via Eagle Capital Partners and CapMan Russia
- **DG Infra+ / DG Infra Yield:**
investments in infrastructure and related assets in the Benelux
- **Other funds:**
in, amongst others, the UK and Scandinavia

Investment team

- **Patrick Van Beneden**
Executive Vice-President Life Sciences
- **Jim Van heusden**
Partner
- **Annegret de Baey-Diepolder**
Partner
- **Christophe Van Vaeck**
Senior Investment Manager

The Life Sciences division can call upon the expertise of all of Gimv's specialist teams and the in-house legal team.

About Gimv

- European investment firm established in 1980
- EUR 1.8 billion assets under management
- listed on NYSE Euronext Brussels (share code GIMB)
- strong international network
- experienced teams
- 4 offices:
Belgium (Antwerp)
The Netherlands (The Hague)
France (Paris)
Germany (Frankfurt)
- also present in:
Germany (Munich)
Central Europe (Prague)

